SCHEMBL6435857

SCHEMBL6435857

Cc1cc(C)c([N+](=O)[O-])cc1-c1ccc(/C=N\Nc2nc3nonc3nc2Nc2ccccc2F)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.52
KMT2A Q03164 10/20 0.52
MEN1 O00255 9/20 0.52
NPSR1 Q6W5P4 1/20 0.52
BIRC5 O15392 1/20 0.51
ALDH1A1 P00352 7/20 0.45
RAB9A P51151 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
KDM4E B2RXH2 3/20 0.45
POLB P06746 3/20 0.45
RECQL P46063 2/20 0.45
HPGD P15428 2/20 0.45
NPC1 O15118 1/20 0.45
GAA P10253 4/20 0.45
NSD2 O96028 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
TDP1 Q9NUW8 3/20 0.39
LMNA P02545 1/20 0.39
MCL1 Q07820 1/20 0.38
CYP1A2 P05177 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6435861 1.00 MAPT (0.52) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL13310261 0.88 BIRC5 (0.50) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL6507461 0.75 BIRC5 (0.67) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL6507458 0.75 BIRC5 (0.67) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL6419595 0.75 MAPT (0.46) MAPTKMT2AMEN1NPSR1ALDH1A1
SCHEMBL6419602 0.75 MAPT (0.46) MAPTKMT2AMEN1NPSR1ALDH1A1
SCHEMBL6415002 0.74 BIRC5 (0.46) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL6415008 0.74 BIRC5 (0.46) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL6418352 0.74 BIRC5 (0.60) MAPTKMT2AMEN1NPSR1BIRC5
SCHEMBL6414365 0.73 GAA (0.55) MAPTKMT2AMEN1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KMT2A 3640/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.